Business Context and Reporting Period
This Form 8-K was filed by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) on March 13, 2019. The filing serves to report the company's financial results for the three-month period and the fiscal year ended December 31, 2018, as detailed in a press release attached as Exhibit 99.1.
Key Financial Metrics
The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the provided source text.
Material Changes
No specific material changes versus prior periods are quantified in the filing text. The document solely announces the issuance of the financial results press release.
Guidance, Outlook, and Risks
The filing does not provide specific guidance, outlook, management commentary, or risk factors within the text provided. It notes that the attached press release is furnished under Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings.
Investor Verification Checklist
- Verify the correct registrant name is Miragen Therapeutics, Inc., not Viridian Therapeutics, Inc.
- Review the attached Exhibit 99.1 (Press Release) for actual financial figures, as they are absent from the 8-K text.
- Confirm the reporting period covers the quarter and full year ended December 31, 2018.
- Note that the press release is not legally "filed" under Section 18 of the Exchange Act.